Article Details
Retrieved on: 2023-11-17 20:10:31
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
Vigil Neuroscience Inc (NASDAQ: VIGL) shares are down after the company released interim data from its Phase 2 IGNITE proof-of-concept clinical ...
Article found on: www.benzinga.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here